- Recruiting
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
Updated: Sep 16, 2022
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
Newly Diagnosed Multiple Myeloma
Relapsed Refractory Multiple Myeloma
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
Sponsor
Janssen Research & Development, LLC
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT04722146
Official Title: A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
First Posted : January 25, 2021
Click here for details on ClinicalTrials.gov
Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957
JNJ 64007957
JNJ-64007957
JNJ64007957
Teclistamab
Nirogacestat
* Bortezomib (Velcade)
* Lenalidomide (Revlimid)
* Pomalidomide(Pomalyst)
* Daratumumab (Darzalex)
- Alabama: University of Alabama at Birmingham
- California: University of California San Francisco
- Georgia: Emory University Atlanta
- Indiana: Indiana University Indianapolis
- Missouri: Washington University School of Medicine Saint Louis
- New York: Memorial Sloan-Kettering Cancer Center New York
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- New York: New York Presbyterian / Weill Cornell Medical College New York
- New Jersey: Hackensack University Medical Center
- North Carolina: Levine Cancer Institute Charlotte
- Pennsylvania: University of Pittsburgh Medical Center
- Tennessee: Sarah Cannon Research Institute Nashville
- Washington: Seattle Cancer Care Alliance
- Wisconsin: Medical College Of Wisconsin Milwaukee
Locations
United States, Alabama
United States, California
United States, Colorado
United States, Georgia
United States, Indiana
United States, Kansas
United States, Missouri
United States, New Jersey
United States, New York
United States, North Carolina
United States, Pennsylvania
United States, Tennessee
United States, Washington
United States, Wisconsin
Europe
United Kingdom
France
Belgium
Australia
RELATED POSTS
TECLISTAMAB STUDIES:
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)
NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
TALQUETAMAB STUDIES:
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
TECLISTAMAB AND TALQUETAMAB STUDIES:
NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2